Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Frank O'Brien

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
European Urology|February 12, 2009
Editorial comment on: current applications for prostate-specific antigen doubling timeMatthew Frank O'Brien
European Urology|February 5, 2008
Serum markers for prostate cancer: a rational approach to the literatureThomas Steuber, Matthew Frank O'Brien, Hans Lilja
Urology|November 10, 2007
Squamous cell carcinoma of the renal pelvis after curative retroperitoneal radiotherapy for seminomaBrendan J O'Daly, Matthew Frank O'Brien, Catherine M Dowling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomyMatthew Frank O'Brien, Angel M Cronin, Paul A Fearn, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
European Urology|February 12, 2009
Editorial comment on: current applications for prostate-specific antigen doubling timeMatthew Frank O'Brien
European Urology|February 5, 2008
Serum markers for prostate cancer: a rational approach to the literatureThomas Steuber, Matthew Frank O'Brien, Hans Lilja
Urology|November 10, 2007
Squamous cell carcinoma of the renal pelvis after curative retroperitoneal radiotherapy for seminomaBrendan J O'Daly, Matthew Frank O'Brien, Catherine M Dowling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomyMatthew Frank O'Brien, Angel M Cronin, Paul A Fearn, et al.
Pageof 1